Navigation Links
Lilly Oncology to Unveil More Than 50 Studies at ASCO 2010
Date:5/17/2010

INDIANAPOLIS, May 17 /PRNewswire-FirstCall/ -- Eli Lilly and Company will unveil data from 57 studies at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 4 – 8, 2010, during which the company will present the latest research results on ALIMTA® (pemetrexed for injection) and GEMZAR® (gemcitabine HCl for injection), as well as ERBITUX® (cetuximab) with partners Bristol-Myers Squibb and Merck-Serono.  

Of note are two Phase II ALIMTA studies (ASCO Abstracts #7082 and #7087), which both evaluate ALIMTA plus platinum-based chemotherapy in combination with concurrent radiation therapy in patients with advanced non-small cell lung cancer (NSCLC).  Several studies evaluating GEMZAR in combination with other potential therapies are also slated for presentation at the meeting.  

"Lilly Oncology research teams around the world are committed to finding new ways to improve and prolong the lives of people living with cancer," said John H. Johnson, president of Lilly Oncology.  "We are constantly studying new uses for our established therapies and discovering new molecules – all in the hopes of changing the way we treat cancer."  

In addition to studies on marketed Lilly Oncology products, new data will also be presented at ASCO on several Lilly Oncology molecules in clinical development, namely tasisulam (an anti-cancer agent), and ImClone's ramucirumab and cixutumumab (both are IgG1 monoclonal antibodies).  

Studies of note for ALIMTA include:

  • Abstract #7082: General Poster Session: '/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
2. Lilly Declares Fourth-Quarter Dividend
3. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
5. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
6. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
7. Lilly Announces Termination of AIR Insulin Program
8. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
9. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
10. Lilly Reports Solid First-Quarter Results
11. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... York, NY - July 24, 2014 -- Keryx Biopharmaceuticals, ... from the long-term, randomized, active control Phase 3 study ... iron-based phosphate binder, for the treatment of hyperphosphatemia in ... PERFECTED study (PhosphatE binding and iRon delivery with FErric ... Journal of the American Society of Nephrology ...
(Date:7/24/2014)... PARK, Calif. , July 24, 2014 /PRNewswire/ ... company in the emerging field of regenerative medicine, ... webcast of a presentation to investors on Tuesday, ... p.m. PDT.  The presentation will include an overview ... To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics ...
(Date:7/24/2014)... Yet, scientists are making progress in devising suitable ... approach relies on quantum dotsa kind of artificial ... A new study demonstrates that changing the coupling ... electrical impulses can help better control them. This ... as quantum information units, which would produce faster ...
(Date:7/24/2014)... DUBLIN , July 24, 2014 ... the "Global Genomics and Proteomics Analytical Instruments Market ... http://photos.prnewswire.com/prnh/20130307/600769 Genomics is the ... is the study of the structure and functions of ... and bioinformatics tools and technology. Genomics involves the mapping ...
Breaking Biology Technology:Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2
... 1, 2011 Tengion, Inc. (Nasdaq: TNGN ), ... entered into definitive agreements with certain investors in connection with ... Securities Act of 1933, as amended.  Medtronic (NYSE: ... the financing and, as part of its investment, secured a ...
... Wash., March 1, 2011 Iverson Genetic Diagnostics, Inc. announced ... dverse Event R eduction f or A ... itiation) was initiated at WellStar Health System in Marietta and ... genetic testing to determine a personalized warfarin dose for individual ...
... gold particles are currently intensively investigated for possible ... and molecular electronics. The particles are prepared in ... gold cores can be stabilised with various organic ... using organothiolate ligands that have a strong chemical ...
Cached Biology Technology:Tengion Announces Pricing of $31.4 Million Private Placement 2Tengion Announces Pricing of $31.4 Million Private Placement 3WARFARIN Study Launched at WellStar Health System to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 2WARFARIN Study Launched at WellStar Health System to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 3WARFARIN Study Launched at WellStar Health System to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 4Fingerprints of a gold cluster revealed 2
(Date:7/23/2014)... DIEGO , July 24, 2014 Pfenex Inc. ... public offering of 8,333,333 shares of its common stock at ... addition, Pfenex has granted the underwriters a 30-day option to ... the initial public offering price. The shares are expected to ... under the symbol "PFNX". William Blair ...
(Date:7/23/2014)... Children who have been abused or neglected early ... emotional and physical health problems. In a new ... way genes are activated, which has implications for ... a particular child,s individual characteristics and genetics interacted ... understand how health problems emerge. In the new ...
(Date:7/23/2014)... In Aesop,s fable about the crow and the pitcher, a ... he tries to drink from it, he finds the water ... over the pitcher, the bird drops pebbles into it ... enough for him to drink his fill. , Highlighting the ... often be more effective than brute force. It also characterizes ...
Breaking Biology News(10 mins):Pfenex Inc. Announces Pricing Of Initial Public Offering 2Stress tied to change in children's gene expression related to emotion regulation, physical health 2Stress tied to change in children's gene expression related to emotion regulation, physical health 3Smarter than a first-grader? 2Smarter than a first-grader? 3Smarter than a first-grader? 4
... EAST LANSING, Mich. A repellant for sea lampreys could ... destructive invasive species in the Great Lakes, says a Michigan ... cues have on lampreys. When scents from dead sea lampreys ... efforts to escape are dramatic. In the past, these reactions ...
... used to the fact that most new-born foals suffer from ... including supplementing the mothers, diets with -carotene, which is known ... However, Juliane Kuhl in the group of Christine Aurich at ... this food supplement has no real effect on the incidence ...
... led by Professor Malcolm McConville from the Bio21 Institute, University ... used for many infectious parasites and bacteria. The technique has ... down to the particular atoms it uses as a food ... field because the more we know about these dangerous pathogens ...
Cached Biology News:Sea lampreys fear the smell of death 2No treatment is the best treatment -- diarrhea in young foals 2
... The Polymerase gene from Thermus aquaticus ... in E. coli, then highly purified ... is used in the amplification and ... The quality of the Taq DNA ...
... iTaq DNA polymerase is ... suitable for both conventional and ... is supplied at a concentration ... and includes 5,000 units polymerase, ...
Rabbit polyclonal to hnRNP-U...
... is an antibody-mediated hot-start DNA ... and real-time PCR applications. The ... concentration of 5 units per ... polymerase, 1.25 ml 10x PCR ...
Biology Products: